1-2 of 2 results for subject:Methylphenidate
Librarians' tools
- Search time
- 0.166 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Methylphenidate
- We searched for
- subject_t:Methylphenidate OR subject_t:"Concerta XL" OR subject_t:"Methylphenidate hydrochloride" OR subject_t:Ritalin OR subject_ses:12526
Session
X
2000-01
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, if he will make a statement on the use of (a) Prozac and (b) other psychiatric drugs on children.
To ask the Secretary of State for Health, if he will make a statement on the use of (a) Prozac and (b) other psychiatric drugs on children.
Asked by
Norman Baker
(Liberal Democrat)
Answered by
Lord Hutton of Furness
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
7 March 2001
For answer on
12 March 2001
Answered on
12 March 2001
Mr. Baker: To ask the Secretary of State for Health if he will make a statement on the use of (a) Prozac and (b) other psychiatric
drugs on children. [153260]
Mr. Hutton: Prozac is not licensed for use in children in the United Kingdom. Doctors may prescribe Prozac, outside the normal
licensed indication, if they consider that this is in the patient's best interests.
Other psychotropic drugs are less commonly used in children than adults as the prevalence of severe mental illness is considerably
lower. Methylphenidate (Ritalin) and other similar stimulants are, however, licensed and used for the treatment of the more severe
forms of Attention Deficit Hyperactivity Disorder. The National Institute for Clinical Excellence issued guidance last November on
the use of Methylphenidate.
Subjects
Children; Drugs; Psychiatry; Methylphenidate; Fluoxetine
Date
12 March 2001
Reference
364 c421W; 153260
House
House of Commons
To ask the Secretary of State for Health, what steps NICE is taking to monitor (a) the use of and (b) adverse reactions to Ritalin in children; and if he will make a statement.
To ask the Secretary of State for Health, what steps NICE is taking to monitor (a) the use of and (b) adverse reactions to Ritalin in children; and if he will make a statement.
Asked by
Andrew Love
(Labour; Co-operative Party)
Answered by
Baroness Stuart of Edgbaston
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
21 December 2000
For answer on
11 January 2001
Answered on
11 January 2001
Mr. Love: To ask the Secretary of State for Health what steps NICE is taking to monitor (a) the use of and (b) adverse reactions to
Ritalin in children; and if he will make a statement. [144486]
Ms Stuart: The National Institute of Clinical Excellence does not itself monitor the use of and adverse reactions to particular
medicines. Monitoring the use of medicines is a matter for local clinical governance arrangements. The monitoring of adverse
reactions is carried out by the Committee on Safety of Medicines/ Medicines Control Agency (CSM/MCA). Health professionals are
encouraged to submit voluntarily to the CSM/MCA reports of suspected adverse drug reactions via the yellow card scheme. These
reports, together with data from other sources, are continuously reviewed to identify previously unrecognised hazards or new
information on known hazards which might require regulatory action.
Subjects
Children; Drugs; Prescription drugs; National Institute for Clinical Excellence; Methylphenidate
Date
11 January 2001
Reference
360 c594W;360 c596W; 144486
House
House of Commons